Is green light laser photovaporization (PVP) an appropriate treatment for benign prostatic hyperplasia (BPH)?

GreenLight Laser Photovaporization for BPH

Yes, GreenLight laser photovaporization (PVP) is an appropriate and effective treatment for BPH, with efficacy comparable to TURP at 36 months, particularly advantageous for patients on anticoagulation, high-risk patients, and those desiring shorter hospitalization and catheterization times. 1

Evidence-Based Recommendation

According to the 2023 European Association of Urology Guidelines, GreenLight PVP demonstrates:

• Efficacy equivalent to TURP at 36-month follow-up for symptom improvement 1
• Superior perioperative safety profile with shorter catheterization and hospitalization times, lower transfusion rates, and reduced clot retention episodes 1
• Similar complication rates to TURP for urethral stricture/bladder neck contracture 1
• Comparable ejaculatory dysfunction rates (49.9% vs 56.7% for TURP) 1

Power Settings Matter for Outcomes

Critical distinction: Use 180-W systems for optimal results. The 180-W XPS laser shows reoperation rates comparable to TURP, while the older 120-W HPS laser has significantly higher retreatment rates (11% vs 1.8%, p=0.04) 1. This is clinically significant for long-term patient outcomes.

Specific Clinical Scenarios

High-Risk and Anticoagulated Patients

GreenLight PVP is particularly well-suited for:

• Patients on anticoagulation or antiplatelet therapy (can be performed safely without drug withdrawal) 1, 2
• High-risk surgical candidates 1
• Elderly patients requiring faster recovery 2

Prostate Size Considerations

For prostates <80 mL: GreenLight PVP is a well-established first-line option 1, 3

For prostates >80 mL: The evidence shows mixed results:

• Efficacy remains comparable with similar IPSS improvement and PSA reduction 4
• However, expect higher conversion rates to TURP (4.9% vs 0.3%) and increased transfusion risk (2.4% vs 0%) 4
• When compared directly to HoLEP in prostates >60 mL, PVP showed a 22% conversion rate to TURP and inferior flow rates and post-void residual outcomes 1

For prostates >80 mL, consider HoLEP or ThuLEP as superior alternatives given their prostate size-independent efficacy 1, 5

Important Caveats

Operative Considerations

• Longer operative times compared to TURP 1
• Requires adequate energy density delivery to minimize retreatment risk 6
• Surgeon experience is crucial for larger prostates to avoid conversion and complications 4

When NOT to Use GreenLight PVP

The 2023 AUA Guidelines note that 532 nm GreenLight laser enucleation (distinct from vaporization) remains under evaluation due to lack of high-quality evidence 1, 5

Functional Outcomes

Objective improvements across all prostate sizes:

• IPSS reduction of ≥4 points in 83-90% of patients 4
• Qmax improvement from baseline 7.7 mL/s to 17-19 mL/s at 6 months 3
• PVR reduction from 216 mL to 26-33 mL 3
• PSA drop of approximately 50-60% from baseline 4, 3

These improvements are maintained regardless of baseline post-void residual volume 7

Practical Algorithm

Use GreenLight 180-W PVP when:

1. Prostate volume <80 mL (ideal range)
2. Patient on anticoagulation/antiplatelet therapy
3. High surgical risk patient
4. Patient prioritizes rapid recovery and short hospitalization

Consider alternative (HoLEP/ThuLEP) when:

1. Prostate volume >80 mL
2. Maximum flow rate and complete tissue removal are priorities
3. Lower retreatment risk is essential

Ensure adequate energy delivery and surgeon experience to optimize outcomes and minimize the 4-11% retreatment rates seen with suboptimal technique 1, 6.